

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

| | |
|---|----------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| Sansrosa Pharmaceutical Development, Inc. | 01/09/2012 |
| RECEIVING PARTY DATA | |
| Name: | Galderma Laboratories Inc. |
| Street Address: | 14501 North Freeway |
| City: | Fort Worth |
| State/Country: | TEXAS |
| Postal Code: | 76177 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Application Number: | 10853585 |
| CORRESPONDENCE DATA | |
| Fax Number: | 5168223582 |
| <i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i> | |
| Phone: | 516-822-3550 |
| Email: | jpeterson@hbiplaw.com |
| Correspondent Name: | Hoffmann & Baron, LLP |
| Address Line 1: | 6900 Jericho Turnpike |
| Address Line 4: | Syosset, NEW YORK 11791 |
| ATTORNEY DOCKET NUMBER: | 512-159 A/RCE |
| NAME OF SUBMITTER: | Linda D. Chin |
| Total Attachments: 3 source=512-assignment#page1.tif source=512-assignment#page2.tif source=512-assignment#page3.tif | |

CH \$40.00 10853585

PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT is made by **SANSROSA PHARMACEUTICAL DEVELOPMENT, INC.** a corporation duly organized and existing under the laws of the State of Delaware (hereinafter "SANSROSA") in favor of **GALDERMA LABORATORIES, INC.**, a Delaware corporation (hereinafter "GALDERMA"). SANSROSA and GALDERMA are collectively referred to herein as "the Parties".

WHEREAS, SANSROSA acquired certain interest in the worldwide right, title, and interest in all patents and applications described on the Patent Schedule attached hereto as Exhibit A and incorporated by reference herein (hereinafter referred to as the "Patent Property");

WHEREAS, GALDERMA acquired a certain interest in and said Patent Property of SANSROSA pursuant to a Share Purchase Agreement entered into by the Parties on December 15, 2005; and

WHEREAS, the Parties desire to confirm the sale, transfer, and assignment to GALDERMA of all right, title, and interest in and to SANSROSA's rights in the Patent Property.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby mutually acknowledged, SANSROSA does hereby confirm and does also hereby irrevocably sell, assign, and convey to GALDERMA, its successors and assigns, all its right, title and interest in and to the Patent Property as set forth in Exhibit A for the United States and elsewhere throughout the world, and all rights in any patent or application claiming priority thereto including without limitation all divisional, continuations, continuations-in-part, re-examinations, re-issues and extensions of the Patent Property, and any foreign equivalents thereof.

SANSROSA agrees to execute and promptly deliver at the request of GALDERMA, all documents, and to perform any other reasonable acts GALDERMA may require in order to vest all right, title and interest in and to the Patent Property, in GALDERMA and/or its successor(s).

Assignment of Patents/Applications to Galderma Laboratories, Inc.

EXHIBIT A

| Country | Title | Application Number | Application Date | Patent Number | Grant Date | Docket Number |
|---------------|---|--------------------|------------------|----------------|------------|----------------------------|
| United States | Compounds, Formulations, and methods for Treating or Preventing Inflammatory Skin Disorders | 10/853,585 | 25-May-04 | 7,439,241 | 21-Oct-08 | 512-159 A/RCE |
| China P.R. | Compounds, Formulations, and methods for Treating or Preventing Inflammatory Skin Disorders | 200480021707.5 | 26-May-04 | 200480021707.5 | 08-Sep-10 | 512-159 A/PCT/China |
| China P.R. | Compounds, Formulations, and methods for Treating or Preventing Inflammatory Skin Disorders | 200810167491.3 | 26-May-04 | | | 512-159 A/PCT/China/DIV |
| China P.R. | Compounds, Formulations, and methods for Treating or Preventing Inflammatory Skin Disorders | 201010170787.8 | 26-May-04 | | | 512-159 A/PCT/China/DIV II |
| Israel | Compounds, Formulations, and methods for Treating or Preventing Inflammatory Skin Disorders | 172612 | 26-May-04 | | | 512-159 A/PCT/Israel |
| Mexico | Compounds, Formulations, and methods for Treating or Preventing Inflammatory Skin Disorders | PA/a/2005/14107 | 26-May-04 | | | 512-159 A/PCT/Mexico |
| Norway | Compounds, Formulations, and methods for Treating or Preventing Inflammatory Skin Disorders | 20056104 | 26-May-04 | | | 512-159 A/PCT/Norway |
| Brazil | Compounds, Formulations, and methods for Treating or Preventing Inflammatory Skin Disorders | P10511519-1 | 25-May-05 | | | 512-159 B/PCT/Brazil |
| Canada | Compounds, Formulations, and methods for Treating or Preventing Inflammatory Skin Disorders | 2,567,401 | 25-May-05 | | | 512-159 B/PCT/Canada |
| China P.R. | Compounds, Formulations, and methods for Treating or Preventing Inflammatory Skin Disorders | 200580022382.7 | 25-May-05 | | | 512-159 B/PCT/China |
| Japan | Compounds, Formulations, and methods for Treating or Preventing Inflammatory Skin Disorders | 2007-515279 | 25-May-05 | | | 512-159 B/PCT/Japan |
| Japan | Compounds, Formulations, and methods for Treating or Preventing Inflammatory Skin Disorders | 2011-263425 | 25-May-05 | | | 512-159 B/PCT/Japan/DIV |
| Mexico | Compounds, Formulations, and methods for Treating or Preventing Inflammatory Skin Disorders | PA/a/2006/013649 | 25-May-05 | | | 512-159 B/PCT/Mexico |
| New Zealand | Compounds, Formulations, and methods for Treating or Preventing Inflammatory Skin Disorders | 552325 | 25-May-05 | 552325 | 8-Mar-11 | 512-159 B/PCT/New Zealand |
| South Korea | Compounds, Formulations, and methods for Treating or Preventing Inflammatory Skin Disorders | 2006-7027124 | 25-May-05 | | | 512-159 B/PCT/South Korea |